A company spokesperson tells GlobeSt.com that MDS Proteomics is currently studying two locations in this area for the laboratory and hope to have the facility in operation sometime this year. The lab here would initially have 10 scientists and one business development person housed at the site. The company has projected to grow the workforce to 50 (80% scientists) in the near future.
The facility will focus on high throughput screening, structural biology and drug design, medicinal chemistry and protein identification. The location will also establish a geographic closeness to Partners Healthcare, which has collaborated with MDS Proteomics on how to utilize the study of protein-to-protein pathways to improve patient care, MDS officials note.
The new Denmark facility is a major center of expertise for MDS Proteomics scientists to enhance the understanding of how proteins function at a cellular level. More than 60 scientists occupy the 30,000 sf building.
MDS Proteomics is currently expanding its Toronto presence with a 50,000 sf, state-of-the-art facility for analyzing protein interaction pathways, producing data for its proprietary BIND database to select and validate targets for its partners. The MDS Proteomics' Charlottesville facility will be located in close proximity to the University of Virginia, company officials add.
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to asset-and-logo-licensing@alm.com. For more inforrmation visit Asset & Logo Licensing.
